Login to Your Account



Stemline SL-401 trial succeeds in blastic plasmacytoid dendritic cell neoplasm

By Marie Powers
News Editor

Tuesday, October 31, 2017
in_the_clinic.jpg

All therapies targeting CD123 are not created equally, Stemline Therapeutics Inc. CEO Ivan Bergstein told BioWorld after the company reported top-line data confirming that the phase II pivotal trial of SL-401 hit its primary endpoint for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription